Clinical Study Of Intratracheal Injection Of Pulmonary Surfactant Combined With Budesonide In Prevention And Treatment Of Bronchopulmonary Dysplasia In Premature Infants

Objective: Bronchopulmonary dysplasia(BPD)is one of the common complications of respiratory system in premature infants.A variety of treatment options,including glucocorticoids,are beneficial in reducing the incidence of BPD,but the prevalence of BPD in preterm infants remains high.This article aims to compare the assisted ventilation time,oxygen inhalation time,hospital stay,BPD incidence,and BPD incidence in the two groups after intratracheal instillation of budesonide combined with pulmonary surfactant(PS)and PS alone.And the incidence of complications,clarify the clinical efficacy and safety of budesonide combined with PS in the prevention of BPD in very low birth weight infants,and provide reference for clinical treatment.Method:A retrospective case-control analysis was used.50 patients with very low birth weight who were treated in our hospital from 2017 to October to 2018-6 months and were diagnosed with respiratory distress syndrome were divided into observation group(23 cases)and control group(27 cases).PS(200 mg/kg)and budesonide(0.25 mg/kg)were instilled into the tracheal intubation,and only PS(200 mg/kg)was instilled into the tracheal intubation in the control group.The incidence and severity of BPD at 36 weeks of gestational age were recorded and compared.The PS re-use status,invasive assisted ventilation time,non-invasive assisted ventilation time,oxygen inhalation time and hospitalization time were compared.The incidence of adverse reactions in the two groups.Results:When the gestational age was 36 weeks,the incidence of bronchopulmonary dysplasia in the observation group was significantly lower than that in the control group(P<0.05).There was no significant difference in the incidence of bronchopulmonary dysplasia between the two groups(P> 0.05);There was no significant difference in the re-use of PS between the two groups(P>0.05).The oxygen inhalation time of the observation group was significantly shorter than that of the control group(P<0.05).Invasive assisted ventilation in the two groups There was no significant difference in time,non-invasive assisted ventilation time and hospitalization time(P>0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Budesonide combined with PS can effectively prevent bronchopulmonary dysplasia in very low birth weight infants,and can also reduce oxygen inhalation time,and the incidence of complications such as hypertension,hyperglycemia,gastrointestinal bleeding,sepsis,NEC,severe intracranial hemorrhage and ROP.No significant increase has been seen.